Cancer Evolvability Determines Therapy Outcomes

Area of Science:

• Evolutionary biology
• Cancer research
• Mathematical modeling

Background:

• Cancer progression after treatment failure is an evolutionary process driven by therapy selection pressures.
• Cancer's evolvability, its capacity for variation, dictates adaptation speed and treatment resistance.

Purpose of the Study:

• To model how cancer evolvability influences resistance dynamics under targeted therapy and chemotherapy.
• To evaluate the efficacy of sequential therapy strategies against adaptable (facultative evolvability) cancers.

Main Methods:

• Developed an evolutionary game-theoretic model.
• Compared cancer populations with fixed (low/high) and facultative evolvabilities.
• Simulated an evolutionary double bind strategy using sequential chemotherapy and targeted therapy cycles.

Main Results:

• Targeted therapy is more effective against low-evolvability cancers; chemotherapy better controls high-evolvability populations.
• Facultative evolvability allows cancers to sustain higher tumor burden by dynamically adjusting evolvability.
• An optimized sequence of chemotherapy and targeted therapy can lead to the extinction of facultative evolvability cancers.

Conclusions:

• Cancer evolvability is a critical factor in treatment response and resistance.
• Therapy design must incorporate evolutionary principles to overcome cancer adaptation.
• Sequential therapy strategies offer a promising approach to manage highly adaptable tumors.